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Abstract
Both the recently updated consensus guidelines published by the American College of Chest
Physicians, and the International Union of Angiology recommend thromboprophylaxis with either
low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) in medical patients at risk
of VTE. However, no guidance is given regarding the appropriate dosing regimens that should be
used for thromboprophylaxis in this patient group. LMWH (enoxaparin and dalteparin) and UFH
have been shown to be effective for thromboprophylaxis in at-risk hospitalized medical patients.
Although LMWH once daily (o.d.) has been shown to be as effective as UFH three times daily (t.i.d.)
for thromboprophylaxis in at-risk medical patients, there are no data to show that UFH twice daily
(b.i.d) is as effective as either LMWH o.d. or UFH t.i.d. On the basis of currently available evidence,
the LMWHs enoxaparin and dalteparin are more attractive alternatives to UFH for the prevention
of VTE in hospitalized medical patients because of their convenient once-daily administration and
better safety profile, demonstrated in terms of reduced bleeding, HIT, and other adverse events.
Introduction
In the absence of thromboprophylaxis, the incidence of
venous thromboembolism (VTE) ranges from 10–20% in
general medical patients to 80% in trauma patients, spinal
cord injury patients, and patients in the critical care unit
[1,2]. Despite evidence from large, randomized clinical
studies demonstrating the benefits of providing thrombo-
prophylaxis for hospitalized medical patients at risk of
VTE [3-5], thromboprophylaxis is not currently prescribed
to the extent that might be expected in this patient popu-
lation, leaving many patients exposed to significant risk of
acute thrombotic complications and their long-term con-
sequences [6-9].
Consensus guidelines published by the American College
of Chest Physicians (ACCP) and the International Union
of Angiology (IUA) recommend assessment of all hospi-
talized medical patients for the risk of VTE and the provi-
sion of appropriate thromboprophylaxis [1,2].
Furthermore, simple and clinically-relevant risk assess-
ment models (RAMs) are available to facilitate VTE risk
assessment [10,11]. A recently published evidence-based
RAM, developed specifically for hospitalized medical
patients, should provide additional guidance to physi-
cians in this patients group [12]. This RAM integrates
patient VTE risk level with appropriate thromboprophy-
lactic strategies in the form of a management algorithm.
Computerised reminders have also been shown to be val-
uable for improving prophylaxis prescribing rates [13],
and an electronic risk assessment tool has recently been
developed for use in medical patients as well as surgical
patients [14].
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The recently updated ACCP consensus guidelines give a
grade 1A recommendation for thromboprophylaxis using
either low-molecular-weight heparin (LMWH) or low-
dose unfractionated heparin (UFH) in medical patients
with congestive heart failure (CHF) or severe respiratory
disease, or in medical patients who are confined to bed
and have one or more risk factors for VTE, such as active
malignancy, acute neurological disease, inflammatory
bowel disease, previous VTE, or sepsis [1]. LMWHs, unlike
UFH, have greater bioavailability and consistent anticoag-
ulation effects, and the benefit of once-daily dosing
[15,16].
The aim of this manuscript is to review recent advances in
thromboprophylaxis in hospitalized medical patients,
and discuss them in light of the recently updated ACCP
consensus guidelines.
Heparin-based thromboprohylaxis
Several placebo-controlled studies have investigated the
efficacy of thromboprophylaxis with UFH or LMWH in
medical patients (Table 1) [3-5,17-26]. In general, low-
dose UFH, given subcutaneously (s.c.) twice daily (b.i.d.)
or three times daily (t.i.d.), is effective in the prevention of
VTE [17-21]. Nevertheless, some studies did not show a
reduction in overall mortality [22,23], which led some
physicians to question the value of thromboprophylaxis
in medical patients [25,27].
The efficacy of LMWH thromboprophylaxis in hospital-
ized medical patients has been investigated in several
large, randomized, placebo-controlled clinical studies
(Table 1). Compared with placebo, thromboprophylaxis
with LMWH reduces the risk of VTE by 45–66% [3,4,24-
26]. In the international Prophylaxis in Medical Patients
with Enoxaparin (MEDENOX) study, two doses of enoxa-
Table 1: Randomized studies comparing the efficacy of thromboprophylaxis using LMWH, UFH or fondaparinux with placebo or no 
thromboprophylaxis in medical patients.
Study Patients Detection of VTE Dose regimen Efficacy 
(thromboprophylaxis vs 
placebo or no 
thromboprophylaxis)
Gallus et al.1973 [17] Suspected AMI (n = 78) 125I-fibrinogen scanning UFH, 5000 IU s.c. t.i.d. VTE: 2.6% vs 22.5% (p = 0.05)
Belch et al. 1981 [18] HF and/or chest infection 
(n = 100)
125I-fibrinogen scanning UFH, 5000 IU s.c. t.i.d. VTE: 4% vs 26% (p < 0.01)
Halkin et al. 1982 [19] General medical (n = 1358) Mortality study UFH, 5000 IU s.c. b.i.d. Mortality: 7.8% vs 10.9% (p < 
0.05)
Cade, 1982 [20] 1) Medical (n = 131)
2) Critically ill (n = 119)
125I-fibrinogen scanning UFH, 5000 IU s.c. b.i.d. 1) VTE: 2% vs 10% (p = NS)
2) VTE: 13% vs 29% (p < 0.05)
Ibarra-Perez et al. 1988 
[21]
Pulmonary disease, >40 
years (n = 85)
125I-fibrinogen scanning, 
plus contrast venography
UFH, 5000 IU s.c. b.i.d. VTE: 2.6% vs 26.1% (p < 
0.0022)
Gårdlund, 1996 [22] Infectious disease (n = 
19,751)
Autopsy-verified 
pulmonary embolism
UFH, 5000 IU s.c. b.i.d. Mortality: 5.3% vs 5.6% (p = 
NS)
International Stroke Trial, 
1997 [23]
Suspected acute ischaemic 
stroke (n = 19,435)
Mortality study UFH, 5000 or 12,500 
IU s.c. b.i.d.
14-day mortality: 9% vs 9.3% (p 
= NS)
6-month mortality: 22.5% vs 
21.5% (p = NS)
Dahan et al. 1986 [24] Medical, >65 years (n = 
270)
125I-fibrinogen scanning Enoxaparin 60 mg s.c. 
o.d.
VTE: 3% vs 9% (p = 0.03)
Bergmann and Caulin, 1996 
[25]
Medical (n = 2472) Mortality study; autopsy-
confirmed pulmonary 
embolism
Nadroparin 7500 
antiXa IU s.c. o.d.
Mortality: 10.1% vs 10.3% (p = 
NS)
Samama et al. 1999 [3] Acutely ill medical (n = 
1102)
Bilateral venography or 
duplex ultrasonography
Enoxaparin
1) 20 mg s.c. o.d.
2) 40 mg s.c. o.d.
1) VTE: 15.0% vs 14.9% (p = 
NS)
2) VTE: 5.5% vs 14.9% (p < 
0.001)
Fraisse et al. 2000 [26] Chronic obstructive 
pulmonary disease (n = 
223)
Bilateral venography Nadroparin 3800 or 
5700 IU antiXa s.c. 
o.d.1
VTE: 15.5% vs 28.2% (p = 
0.045)
Leizorovicz et al. 2004 [4] Acutely ill medical (n = 
3706)
Compression 
ultrasonography
Dalteparin 5000 IU s.c. 
o.d.
VTE: 2.8% vs 5.0% (p = 0.0015)
Cohen et al. 2006 [5] Acutely ill elderly medical 
(n = 849)
Bilateral venography Fondaparinux, 2.5 mg 
s.c. o.d.
VTE: 5.6% vs 10.5% (p = 0.029)
1Dose adjusted based on patients' body weight. Patients in the range 45–70 kg received 3800 antiXa IU and patients in the range 71–110 kg received 
5700 antiXa IU (i.e. 0.4 ml or 0.6 ml of a 9500 antiXa IU/ml concentrated solution of nadroparin, respectively).
AMI, acute myocardial infarction; b.i.d., twice daily; HF, heart failure; LMWH, low-molecular-weight heparin; o.d., once daily; s.c. subcutaneously; 
t.i.d., three times daily; UFH, unfractionated heparin; VTE, venous thromboembolism.Thrombosis Journal 2006, 4:8 http://www.thrombosisjournal.com/content/4/1/8
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parin (20 mg and 40 mg s.c. o.d.) were compared with
placebo in acutely ill medical patients [3]. The MEDENOX
study, in which deep-vein thromboses (DVT) were con-
firmed using venography, showed a significant reduction
in the incidence of VTE when 40 mg enoxaparin was used
compared with placebo for 6–14 days (relative risk, 0.37;
97.6% confidence interval (CI), 0.22–0.63; p < 0.001),
but not when 20 mg enoxaparin was used (Table 1). The
benefit with 40 mg enoxaparin was maintained at 3-
month follow-up (relative risk, 0.41; 95% CI, 0.25–0.68;
p < 0.001). Moreover, Kaplan-Meier plots of the probabil-
ity of 3-month survival rates suggest that the overall mor-
tality was lower in patients receiving 40 mg enoxaparin
than those receiving placebo, although differences in mor-
tality rates between the three groups did not reach statisti-
cal significance. A retrospective multihospital analysis of
data from hospitalized acutely ill medical patients in the
USA also showed that thromboprophylaxis with enoxa-
parin resulted in a significant reduction in the incidence
of VTE compared with no thromboprophylaxis (1.9% vs
6.2%, p = 0.023) [28].
The Prospective Evaluation of Dalteparin Efficacy for Pre-
vention of VTE in Immobilized Patients Trial (PREVENT)
later confirmed the benefits of LMWH prophylaxis in hos-
pitalized medical patients. This study, which enrolled a
patient population with a slightly lower thrombotic risk
than those in MEDENOX and used compression ultra-
sound to confirm DVT, showed that a high thrombopro-
phylactic dose of 5,000 IU dalteparin significantly
reduced the incidence of VTE in acutely ill medical
patients compared with placebo (relative risk, 0.55; 95%
CI, 0.38–0.80; p = 0.0015) [4]. However, in contrast to the
findings of the MEDENOX study [3], the reduced inci-
dence of VTE was not statistically significant at the 3-
month follow-up (relative risk, 0.70; 95% CI 0.36–1.35)
and a trend towards reduced mortality was not observed
in the dalteparin group compared with the placebo group
[4]. It is difficult to conclude whether these differences
between the findings of the MEDENOX and PREVENT
studies were a result of different pharmacological proper-
ties of the two LMWHs [29] or differences in the method-
ology and patient characteristics of the two studies.
Several randomized studies have compared the efficacy of
LMWH and UFH as thromboprophylaxis in hospitalized
medical patients at risk of VTE (Table 2) [30-34]. These
studies have all reported that LMWH is at least as effective
as UFH in reducing the risk of VTE. Similarly, a meta-anal-
ysis of randomized studies of thromboprophylaxis with
LMWH or UFH in medical patients confirmed that both
LMWH and UFH are effective in reducing the incidence of
DVT in these patients compared with placebo or no
thromboprophylaxis (relative risk, 0.44; 95% CI, 0.29–
0.64;  p  < 0.001) [35]. This meta-analysis also demon-
strated that the rate of pulmonary embolism (PE) was sig-
nificantly reduced by LMWH or UFH compared with
placebo (relative risk, 0.48; 95% CI, 0.34–0.68; p < 0.001)
[35]. No significant differences in the incidences of DVT
or PE in patients receiving LMWH compared with UFH
were observed (relative risk for DVT, 0.83; 95% CI, 0.56–
1.24; p = 0.37; relative risk for PE, 0.74; 95% CI, 0.79–
1.88; p = 0.52). It should be noted that this meta-analysis
did not include data from the MEDENOX and PREVENT
studies, and it also has some limitations in terms of differ-
ences in study designs and the small size of some of the
studies included. Nevertheless, it does provide an impor-
tant insight into the impact of heparin therapy on VTE risk
in medical patients. Notably, a recent post-hoc  analysis
demonstrated that asymptomatic proximal DVT, which
was more commonly diagnosed than symptomatic DVT
in acutely ill medical patients in the major clinical studies
mentioned above [3,4], is associated with increased mor-
tality [36]. This adds weight to the clinical opinion that
asymptomatic proximal DVT is a relevant surrogate end-
point for symptomatic thromboembolic disease.
Table 2: Randomized studies of thromboprophylaxis with LMWH compared with UFH in medical patients.
Study Patients LMWH UFH LMWH as 
effective as UFH?*
Harenberg et al. 1990 [30] Hospitalised, bedridden medical (n 
= 166)
Dalteparin 1500 aPTT units 
s.c. o.d.
5000 IU s.c. t.i.d. Yes
Bergmann and Neuhart, 1996 [31] Elderly, bedridden, acutely ill 
medical (n = 442)
Enoxaparin 20 mg s.c. o.d. 5000 IU s.c. b.i.d. Yes
Lechler et al. 1996 [32] Medical (n = 959) Enoxaparin 40 mg s.c. o.d. 5000 IU s.c. t.i.d. Yes
Harenberg et al. 1996 [33] Hospitalised, bedridden medical (n 
= 1968)
Nadroparin 36 mg s.c. o.d. 5000 IU s.c. t.i.d. Yes
Kleber et al. 2003 [34] Severe respiratory disease or acute 
heart failure (n = 665)
Enoxaparin 40 mg s.c. o.d. 5000 IU s.c. t.i.d. Yes
*Efficacy defined as the incidence of objectively confirmed VTE in all studies.
aPTT, activated partial thromboplastin time; b.i.d., twice daily; LMWH, low-molecular-weight heparin; o.d., once daily; s.c., subcutaneously; t.i.d., 
three times daily; UFH, unfractionated heparin; VTE, venous thromboembolism.Thrombosis Journal 2006, 4:8 http://www.thrombosisjournal.com/content/4/1/8
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Thromboprophylactic regimens for medical patients
Although the recently updated ACCP consensus guide-
lines recommend thromboprophylaxis with either LMWH
or UFH for at-risk medical patients, no recommendations
are given regarding appropriate dosing regimens [1]. The
ACCP guidelines' grade 1A recommendations are based in
part on randomized clinical studies of thromboprophy-
laxis with LMWH given s.c. o.d. versus UFH given s.c. t.i.d.
in medical patients. These studies showed that LMWH s.c.
o.d. and UFH s.c. t.i.d. have similar efficacy and, therefore,
both received a grade 1A recommendation. Despite these
evidence-based guidelines, many physicians still use b.i.d.
dosing for UFH in medical patients. This is probably due
to data from earlier placebo-controlled clinical studies of
UFH (Table 1), which showed that b.i.d. dosing with UFH
was effective in reducing the risk of VTE in these patients
[19-21].
When comparing UFH and LMWH, similar efficacy in the
prevention of VTE in medical patients has only been
observed when UFH t.i.d. was compared with LMWH o.d.
(Table 2). One study did show that LMWH o.d. was as
effective as UFH b.i.d. at preventing VTE in medical
patients [31]. However, the dose of LMWH used was 20
mg enoxaparin s.c. o.d., a dose which the MEDENOX
study showed to be ineffective for preventing VTE in
acutely ill medical patients [3].
These findings were confirmed in a recently published sys-
tematic review of published randomized clinical trials
evaluating the efficacy of UFH 5000 IU b.i.d., compared
with LMWH and UFH 5000 IU t.i.d. [37]. Although UFH
b.i.d. reduced the relative risk of VTE compared with pla-
cebo (relative risk 0.40, 95% CI 0.22–0.73), it was less
effective than UFH t.i.d, versus placebo (relative risk 0.28,
95% CI 0.21–0.38). In studies comparing UFH 5000 IU
t.i.d. with enoxaparin 40 mg o.d., enoxaparin was more
effective at reducing the risk of VTE (relative risk 1.42;
95% CI 0.99–2.05).
In light of this, it is noteworthy that there are data to sug-
gest better efficacy with enoxaparin than with UFH given
on a t.i.d. basis to patients with congestive heart failure
(CHF). When comparing enoxaparin 40 mg o.d. with
UFH in patients with CHF in THE-PRINCE study, enoxa-
parin 40 mg o.d. showed a trend towards better efficacy
than UFH, t.i.d. (Figure 1). Venous thromboembolic
events occurred in 9.7% of the patients with CHF receiv-
ing enoxaparin 40 mg compared with 16.1% of those
receiving UFH, although the patient numbers were too
small to show a statistically significant difference between
groups [34]. In patients with CHF in the MEDENOX study
[3], which did not have a UFH arm, 40 mg enoxaparin
resulted in a significant reduction in the incidence of VTE
compared with placebo (relative risk, 0.29; 95% CI, 0.10–
0.84; Figure 1) [38]. The lower incidence of VTE in CHF
patients receiving enoxaparin 40 mg compared with either
placebo or UFH warrants further investigation in a rand-
omized clinical trial with sufficient power to show supe-
rior efficacy of enoxaparin, 40 mg o.d., compared with
UFH, t.i.d., in CHF patients. It should also be noted that
while the definitions of CHF patients were the same in
these two studies, more patients presented with New York
Heart Association (NYHA) class III-IV or IV in THE-
PRINCE study than in the MEDENOX study (64.0% vs
20.2%). In addition, patients in THE-PRINCE study had
more additional thrombotic risk factors, such as obesity
(30% vs 20%) and pre-existing chronic venous disease
(40% vs 25%). This may explain the higher incidence of
VTE in patients with CHF in the enoxaparin, 40 mg o.d.,
arm of THE-PRINCE study (9.7%), compared with the
enoxaparin 40 mg o.d. arm of the MEDENOX study
(4.0%).
In summary, only the t.i.d. regimen of UFH is supported
by similar clinical outcomes compared with LMWH o.d..
Therefore, only UFH t.i.d. amd LMWH o.d. (enoxaparin
or dalteparin) and can be recommended for use as throm-
boprophylaxis in hospitalized medical patients at risk of
VTE.
Incidence of VTE in congestive heart failure patients from the  MEDENOX and THE-PRINCE studies [3, 34] Figure 1
Incidence of VTE in congestive heart failure patients from the 
MEDENOX and THE-PRINCE studies [3, 34]. P-values were 
calculated using Fisher's exact test comparing pooled enoxa-
parin 40 mg data from the MEDENOX and THE-PRINCE 
studies with the placebo data from MEDENOX and the UFH 
data from THE-PRINCE. UFH, unfractionated heparin; VTE, 
venous thromboembolism.
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Thromboprophylaxis with other anticoagulants
Although most studies on thromboprophylaxis in acutely
ill medical patients have investigated the efficacy of
LMWHs, a placebo-controlled trial of the synthetic factor
Xa inhibitor fondaparinux (the Arixtra for Thromboem-
bolism Prevention in a Medical Indications Study
[ARTEMIS]) has recently been published [5]. The
ARTEMIS study, which used venography to confirm DVT,
showed a significant reduction in the incidence of VTE in
elderly acutely ill medical patients receiving fonda-
parinux, 2.5 mg o.d., compared with placebo (5.6% vs.
10.5%, respectively, p  = 0.029; relative risk reduction
46.7%; 95% CI 7.7%-69.3%) (Table 1) [5]. There was also
a significant reduction in the incidence of symptomatic
fatal or non-fatal pulmonary embolism in the fonda-
parinux group compared with the placebo group (1% vs.
3%, p = 0.029). Patient inclusion criteria in ARTEMIS dif-
fered from those used in the MEDENOX and PREVENT
studies: patients were older (>60 years compared to >40
years) and were immobilised for longer (>4 days com-
pared with ≤ 3 days) [3-5]. This may explain the high mor-
tality rate in the placebo group of the ARTEMIS study;
almost twice as many deaths occurred in the placebo arm
compared with the fondaparinux arm (6.0% vs 3.3%, p =
0.06) [5]. Considering that the efficacy of thromboproph-
ylaxis with LMWH or UFH is now firmly established in
medical patients at risk of VTE, and that thromboprophy-
laxis with LMWH or low-dose UFH has a grade 1A recom-
mendation from the ACCP consensus guidelines, the
ethics of including a placebo arm in a study of this patient
group is now questionable. Currently, only UFH, enoxa-
parin and dalteparin are approved for use in the preven-
tion of VTE in medical patients. Further studies comparing
fondaparinux with UFH or LMWH are awaited.
Safety of thromboprophylaxis
Low-molecular-weight heparin o.d. has similar efficacy to
UFH t.i.d. when used as thromboprophylaxis. However,
several randomized clinical studies have shown that
LMWH has a better safety profile than UFH (Table 3) [30-
34]. In the Thromboembolism Prophylaxis in Internal
Medicine with Enoxaparin (THE PRIME) study, bleeding
events were similar between both treatment groups, but
injection-site haematomas >5 cm were more frequently
reported in patients who received UFH compared with
those who received enoxaparin 40 mg o.d. (10.8% vs
4.6%, p < 0.001) [32]. Several other studies have reported
similar results (Table 3).
In the previously described meta-analysis of randomized
studies that showed equivalent thromboprophylactic effi-
cacy when directly comparing LMWH and UFH [35], use
of LMWH also reduced the relative risk of major haemor-
rhage by 52% compared with UFH (relative risk, 0.48;
95% CI, 0.23–1.00; p = 0.049) [35]. Another, more recent,
analysis pooled safety data from 2,346 patients from the
MEDENOX, THE-PRINCE, and THE PRIME studies to
determine the risk of haemorrhage following thrombo-
prophylaxis with UFH or enoxaparin [39]. While the inci-
dence of major haemorrhage was similar in patients given
enoxaparin, UFH, or placebo, the incidence of minor
bleeding associated with UFH was significantly greater
than that associated with enoxaparin (relative risk, 1.7;
95% CI, 1.3–2.2; p = 0.0001).
The ARTEMIS study [5] reported a low risk of bleeding
complications when elderly acutely ill medical patients
were given thromboprophylaxis with fondaparinux 2.5
mg o.d.: major bleeding occurred in one patient in the
fondaparinux group (0.2%) and one in the placebo group
(0.2%). Minor bleeding occurred in 11 patients (2.6%) in
the fondaparinux group and four in the placebo group
(1.0%) [5].
The risk of heparin-induced thrombocytopenia (HIT)
should also be considered when providing patients with
thromboprophylaxis. The risk of HIT has been shown to
be significantly lower in surgical patients receiving LMWH
prophylaxis than in those receiving UFH [40]. Recent
studies, however, suggest that the incidence of HIT in
UFH-treated medical patients may be lower than in surgi-
cal patients [31,41]. Nevertheless, HIT remains an impor-
tant medical issue because of the associated risk of
thromboembolic events. A recent prospective cohort
study reported that the incidence of HIT in hospitalized
medical patients receiving subcutaneous UFH was less
than 1%, but HIT was associated with a high incidence
(60%) of thromboembolic events [41].
Cost-effectiveness of thromboprophylaxis
Several economic studies have examined the cost-effec-
tiveness of thromboprophylaxis in medical patients [42-
45]. Three studies based on data from the MEDENOX
study [3] showed that thromboprophylaxis with enoxa-
parin (40 mg s.c. o.d.) was cost-effective compared with
placebo when examined from French, Canadian and
Spanish cost perspectives [42-44]. A UK study of com-
bined data from the MEDENOX study and a meta-analysis
by Mismetti et al [35] showed that enoxaparin (40 mg s.c.
o.d.) was associated with fewer VTE events and lower costs
compared with no thromboprophylaxis [45] and was cost
neutral compared with UFH.
Conclusion
Evidence from clinical studies has shown the benefits of
thromboprophylaxis with LMWH (enoxaparin and
dalteparin) or UFH for the prevention of VTE in at-risk
medical patients. Thromboprophylaxis with LMWH is as
effective as UFH at preventing VTE in this group of
patients, but has a significantly better safety profile. IfThrombosis Journal 2006, 4:8 http://www.thrombosisjournal.com/content/4/1/8
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UFH is used, physicians should choose a t.i.d. dose regi-
men, as there are no data to show that UFH b.i.d. is as
effective as LMWH o.d. or UFH t.i.d. dosing. Recent data
suggest that fondaparinux may be an effective and safe
option in high-risk elderly medical patients, but further
studies are awaited before general recommendations can
be given regarding its use in all acutely ill medical
patients. On the basis of currently available evidence, it
appears that, while low-dose UFH is also recommended
by the ACCP [1] although without specifying a dose regi-
men, the LMWHs enoxaparin and dalteparin may be
more attractive alternatives for the prevention of VTE in
medical patients because of their convenient once-daily
administration and better safety profile, in terms of fewer
bleeding complications, and a lower risk of HIT and other
adverse events.
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